by | May 31, 2024 | Publications
Clin Hematol Int. 2024 Jan 31;6(1):23-25. doi: 10.46989/001c.92586. eCollection 2024. NO ABSTRACT PMID:38817702 | PMC:PMC11086987 | DOI:10.46989/001c.92586
by | May 31, 2024 | Publications
Clin Hematol Int. 2024 Jan 12;6(1):13-15. doi: 10.46989/001c.92050. eCollection 2024. NO ABSTRACT PMID:38817705 | PMC:PMC11084537 | DOI:10.46989/001c.92050
by | May 31, 2024 | Publications
Front Pharmacol. 2024 May 16;15:1377370. doi: 10.3389/fphar.2024.1377370. eCollection 2024. ABSTRACT Background: Significant progress has been achieved in the management of multiple myeloma (MM) by implementing high-dose therapy and stem cell transplantation....
by | May 30, 2024 | Publications
Chem Res Toxicol. 2024 May 30. doi: 10.1021/acs.chemrestox.4c00142. Online ahead of print. ABSTRACT Multiple myeloma is a hematological cancer that can be treated but remains incurable. With the advancement of science and technology, more drugs have been developed for...
by | May 30, 2024 | Publications
Leuk Lymphoma. 2024 May 30:1-8. doi: 10.1080/10428194.2024.2358857. Online ahead of print. ABSTRACT This study explored the impact of different maintenance therapies on survival outcomes in patients with multiple myeloma (MM), focusing on changes in minimal residual...
by | May 30, 2024 | Publications
Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19570. Online ahead of print. ABSTRACT Therapeutic strategies for patients with newly diagnosed multiple myeloma (NDMM) have considerably improved during the last 10 years. The IFM2014-03 trial proposed an all-oral triplet...
